SALT LAKE CITY, July 22, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian N. Hobden, Ph.D. has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective July 21, 2011. The Board of Directors has appointed Robert J. Lollini, the Company’s Chief Financial Officer, as interim President and Chief Executive Officer. Mr. Lollini will also continue has duties as Chief Financial Officer. The Board plans to initiate a search for a new CEO, looking at both internal and external candidates. In addition, Dr. Hobden has agreed to serve as a consultant to the company for three months to assist in the transition. “On behalf of
